Roivant SciencesROIV +0.29%55 Forward PE Ratio is 0.00 as of Jul. 04, 2026. GuruFocus rates ROIV with a GF Score™ of 55/100 and a GF Value™ of $11.11 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 355 Biotechnology companies, Roivant Sciences ranks worse than 281689.86% on this metric.
Roivant Sciences (NAS:ROIV) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Roivant Sciences Forward PE Ratio Related Terms
Roivant Sciences Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Roivant Sciences's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences Forward PE Ratio Chart
Roivant Sciences Annual Data
Trend
Forward PE Ratio
Roivant Sciences Quarterly Data
Forward PE Ratio
ROIV vs RPRX, BNTX, INCY: Forward PE Ratio Comparison
For the Biotechnology subindustry, Roivant Sciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Roivant Sciences (ROIV) has a Forward PE Ratio of 0.00 as of Jul. 04, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Roivant Sciences and its competitors. According to the industry distribution chart, Roivant Sciences ranks #999999 out of 355 companies in the Biotechnology industry.
Is Roivant Sciences' Forward PE Ratio too high?
Roivant Sciences' current Forward PE Ratio is 0.00. Based on the distribution chart, Roivant Sciences ranks #999999 out of 355 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Roivant Sciences has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Forward PE Ratio compare to RPRX and BNTX?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #999999 out of 355 companies for Forward PE Ratio. This places Roivant Sciences in the lower half of its industry. The industry median Forward PE Ratio is 22.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.47, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Roivant Sciences and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roivant Sciences's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.11, compared to a current price of $35.14 — trading 216.3% above its estimated fair value. The current Forward PE Ratio is 0.00. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Forward PE Ratio is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roivant Sciences (ROIV) Overvalued in 2026?
Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued.
The current stock price of $35.14 is trading 216.3% above its estimated GF Value™ of $11.11.
GuruFocus considers Roivant Sciences to be Significantly Overvalued.
Key valuation signals for ROIV:
Forward PE Ratio: 0.00
GF Value™: $11.11 vs. price of $35.14 (216.3% above fair value)
No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score
Get the complete analysis for ROIV
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROIV has been successfully added to your 